Analyst firms · Morgan Stanley · GMAB

Morgan Stanley GMAB price target and rating history

Genmab A/S (GMAB) · Health Care

Morgan Stanley rates Genmab A/S (GMAB) Equal-Weight with a $34 price target, as of its latest action on Feb 17, 2026. It has published 4 rating actions on GMAB since September 2021, including 0 upgrades and 1 downgrade. Across 6 firms with a GMAB price target in the last 12 months, the median target is $40. Morgan Stanley's $34 is 15% below that.

Current rating
Equal-Weight
Price target
$34
Median target, all firms
$40
Actions on GMAB
4

Morgan Stanley price target on GMAB

$37$34$3120222023202420252026
Morgan Stanley price target on GMAB, each point a stated target, September 2021 to February 2026.

Every Morgan Stanley rating on GMAB

How other firms rate GMAB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
TD CowenBuy$43Jul 22, 2026
Truist SecuritiesBuy$40May 27, 2026
Goldman SachsBuyApr 22, 2026
Wolfe ResearchOutperform$32Mar 27, 2026
Wells FargoOverweight$40Mar 2, 2026
JefferiesBuy$41.50Feb 17, 2026
Morgan StanleyEqual-Weight$34Feb 17, 2026

Questions about Morgan Stanley and GMAB

What is Morgan Stanley's price target for GMAB?
Morgan Stanley's latest stated price target for Genmab A/S (GMAB) is $34, from its action on Feb 17, 2026.
What is Morgan Stanley's rating on GMAB?
Morgan Stanley rates GMAB Equal-Weight, a neutral rating, as of Feb 17, 2026.
When did Morgan Stanley last change its view on GMAB?
On Feb 17, 2026, Morgan Stanley resumes coverage at Equal-Weight, price target $34.
How does Morgan Stanley's GMAB target compare with other analysts?
Across 6 firms with a GMAB price target in the last 12 months, the median target is $40. Morgan Stanley's $34 is 15% below that.

More GMAB rating histories

All Morgan Stanley ratingsGMAB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.